A miR-210-3p regulon that controls the Warburg effect by modulating HIF-1α and p53 activity in triple-negative breast cancer

被引:93
|
作者
Du, Ye [1 ]
Wei, Na [1 ]
Ma, Ruolin [1 ]
Jiang, Shuheng [2 ]
Song, Dong [1 ]
机构
[1] First Hosp Jilin Univ, Dept Breast Surg, Changchun 130021, Jilin, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Ren Ji Hosp,Sch Med, Shanghai 200240, Peoples R China
基金
中国国家自然科学基金;
关键词
CELL; EXPRESSION;
D O I
10.1038/s41419-020-02952-6
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Reprogrammed energy metabolism, especially the Warburg effect (aerobic glycolysis), is an emerging hallmark of cancer. Different from other breast cancer subtypes, triple-negative breast cancer (TNBC) exhibits high metabolic remodeling, increased aggressiveness and lack of targeted therapies. MicroRNAs (miRNA) are essential to TNBC malignant phenotypes. However, little is known about the contribution of miRNA to aerobic glycolysis in TNBC. Through an integrated analysis and functional verification, we reported that several miRNAs significantly correlates to the Warburg effect in TNBC, including miR-210-3p, miR-105-5p, and miR-767-5p. Ectopic expression of miR-210-3p enhanced glucose uptake, lactate production, extracellular acidification rate, colony formation ability, and reduced serum starvation-induced cell apoptosis. Moreover, GPD1L and CYGB were identified as two functional mediators of miR-210-3p in TNBC. Mechanistically, miR-210-3p targeted GPD1L to maintain HIF-1 alpha stabilization and suppressed p53 activity via CYGB. Ultimately, miR-210-3p facilitated aerobic glycolysis through modulating the downstream glycolytic genes of HIF-1 alpha and p53. Taken together, our results decipher miRNAs that regulate aerobic glycolysis and uncover that miR-210-3p specifically contributes to the Warburg effect in TNBC.
引用
收藏
页数:12
相关论文
共 50 条
  • [11] The expression of MELK, a growth regulator of triple-negative breast cancer, is regulated by p53
    Bollu, Lakshmi Reddy
    Brown, Powel H.
    Mazumdar, Abhijit
    Zhao, Dekuang
    Ma, Yanxia
    CANCER RESEARCH, 2017, 77
  • [12] Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer
    Bae, Soo Youn
    Nam, Seok Jin
    Jung, Yongsik
    Lee, Sae Byul
    Park, Byung-Woo
    Lim, Woosung
    Jung, Sung Hoo
    Yang, Hsien Wen
    Jung, Seung Pil
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 172 (02) : 437 - 444
  • [13] Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer
    Soo Youn Bae
    Seok Jin Nam
    Yongsik Jung
    Sae Byul Lee
    Byung-Woo Park
    Woosung Lim
    Sung Hoo Jung
    Hsien Wen Yang
    Seung Pil Jung
    Breast Cancer Research and Treatment, 2018, 172 : 437 - 444
  • [14] Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    Synnott, N. C.
    Murray, A.
    McGowan, P. M.
    Kiely, M.
    Kiely, P. A.
    O'Donovan, N.
    O'Connor, D. P.
    Gallagher, W. M.
    Crown, J.
    Duffy, M. J.
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (01) : 234 - 246
  • [15] A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness
    di Gennaro, Alessandra
    Damiano, Valentina
    Brisotto, Giulia
    Armellin, Michela
    Perin, Tiziana
    Zucchetto, Antonella
    Guardascione, Michela
    Spaink, Herman P.
    Doglioni, Claudio
    Snaar-Jagalska, B. Ewa
    Santarosa, Manuela
    Maestro, Roberta
    CELL DEATH AND DIFFERENTIATION, 2018, 25 (12): : 2165 - 2180
  • [16] A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness
    Alessandra di Gennaro
    Valentina Damiano
    Giulia Brisotto
    Michela Armellin
    Tiziana Perin
    Antonella Zucchetto
    Michela Guardascione
    Herman P. Spaink
    Claudio Doglioni
    B. Ewa Snaar-Jagalska
    Manuela Santarosa
    Roberta Maestro
    Cell Death & Differentiation, 2018, 25 : 2165 - 2180
  • [17] Overexpression of miR-181a regulates the Warburg effect in triple-negative breast cancer
    Wang, Y.
    Tahiri, H.
    Yang, C.
    Gu, M.
    Ruan, X.
    Hardy, P.
    CLIMACTERIC, 2023, 26 (01) : 64 - 71
  • [18] Targeting triple negative breast cancer: Is p53 the answer?
    Turner, Natalie
    Moretti, Erica
    Siclari, Olimpia
    Migliaccio, Ilenia
    Santarpia, Libero
    D'Incalci, Maurizio
    Piccolo, Stefano
    Veronesi, Andrea
    Zambelli, Alberto
    Del Sal, Gianni
    Di Leo, Angelo
    CANCER TREATMENT REVIEWS, 2013, 39 (05) : 541 - 550
  • [19] Immunohistochemical status of p53 as prognostic factor in patients with node negative triple-negative breast cancer
    Bae, S. Y.
    Lee, J. E.
    Lee, S. K.
    Nam, S. J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [20] Deregulated MicroRNAs involved in P53 Signaling Pathway in Breast Cancer with Focus on Triple-negative Breast Cancer
    Naeimzadeh, Yasaman
    Heidari, Zahra
    Razban, Vahid
    Khajeh, Sahar
    CURRENT MOLECULAR PHARMACOLOGY, 2024, 17